deltatrials
Completed PHASE2 NCT00306319

Pharmacokinetic Interaction Study in Indonesian Tuberculosis Patients Indonesia

Pharmacokinetic Interaction Study of Rifampicin, Isoniazid and Moxifloxacin in Tuberculosis Patients in Bandung, Indonesia

Sponsor: Radboud University Medical Center

Conditions Tuberculosis
Interventions moxifloxacin
Updated 7 times since 2017 Last updated: Nov 9, 2020 Started: Jan 31, 2006 Primary completion: May 31, 2006 Completion: May 31, 2006

A PHASE2 clinical study on Tuberculosis, this trial is completed. The trial is conducted by Radboud University Medical Center and has accumulated 7 data snapshots since 2006. Infectious disease trials contribute critical data for public health response and treatment development.

Change History

7 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  3. Mar 2022 — Jul 2024 [monthly]

    Completed PHASE2

  4. Jan 2021 — Mar 2022 [monthly]

    Completed PHASE2

  5. Dec 2020 — Jan 2021 [monthly]

    Completed PHASE2

▶ Show 2 earlier versions

  1. Jun 2018 — Dec 2020 [monthly]

    Completed PHASE2

  2. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE2

    First recorded

Jan 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Radboud University Medical Center
Data source: Radboud University Medical Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Bandung, Indonesia